The Proteins of Type IV Secretion System as Promising Candidates for Helicobacter Pylori Vaccine

Davood Esmaeili

Authors

Davood Esmaeili

Keywords:

Abstract

Helicobacter. pylori is a component of class 1 carcinogens and there is a close association between the incidence of gastric cancer and high prevalence of infection with this bacterium. The risk of gastric cancer associated with H. pylori infection in industrialized and developing countries is estimated to be 80% and 70% respectively. CagA is the important virulence factor in this bacterium and all of the strains involved in gastric cancer are CagA positive. This factor is secreted into host cells by type IV secretion system. CagA and type IV secretion system in H. pylori encoded by the cag pathogenicity islands (cag PAI) that encodes 30 proteins which are necessary for the pilus formation and function of type IV secretion system, so regarding to the role of this secretion system in secreting CagA and its function in pathogenesis and cancer development in humans and the role of different proteins of this secretion system such as canal and pilus formation and their necessity for function of these structures, it is possibly they are be appropriate candidates for design vaccine, because with inhibiting these proteins can stop canal and pilus formation and finally hinder CagA secretion into the host cells.

Downloads

How to Cite

The Proteins of Type IV Secretion System as Promising Candidates for Helicobacter Pylori Vaccine. (2015). Global Journal of Medical Research, 15(C3), 39-42. https://medicalresearchjournal.org/index.php/GJMR/article/view/944

Download Citation

References

Ji-Ping Cai, Jin-Wei Cheng, Xiao-Ye Ma, Yu-Zhen Li, You Li, Xiao Huang, Rui-Li Wei (2012) Lack of association of conjunctival MALT lymphoma with Chlamydiae or Helicobacter pylori in a cohort of Chinese patients. 18(2), BR84-BR88.

D Makola, D Peura, S Crowe (2007) Helicobacter pylori infection and related gastrointestinal diseases. 41(6), 548-558.

Yoshan Moodley, Bodo Linz, Robert Bond, Martin Nieuwoudt, Himla Soodyall, Carina Schlebusch, Steffi Bernhöft, James Hale, Sebastian Suerbaum, Lawrence Mugisha, Schalk Van Der Merwe, Mark Achtman (2012) Age of the Association between Helicobacter pylori and Man. 8(5), e1002693.

L Pacifico, C Anania, J Osborn, F Ferraro, C Chiesa (2010) Consequences of Helicobacter pylori infection in children. 16(41), 5181.

T Azuma, J Konishi, Y Tanaka, M Hirai, S Ito, T Kato (1994) Contribution of HLA-DQA gene to host's response against Hellcobacter pylori. 343(8896), 542-543.

Benjamin Chun-Yu Wong, Shiu Lam, Wai Wong, Jian Chen, Ting Zheng, Rui Feng, Kam Lai, Wayne Hu, Siu Yuen, Suet Leung, Daniel Fong, Joanna Ho, Chi Ching, Jun Chen, For The China Gastric Cancer Study Group (2004) Helicobacter pylori Eradication to Prevent Gastric Cancer in a High-Risk Region of China. 291(2), 187.

D Parkin, C Muir, S Whelan, Y Gao, J Ferlay, J Powell (1992) Cancer incidence in five continents. VI.

A De Luca, A Baldi, P Russo, A Todisco, L Altucci, N Giardullo (2003) Coexpression of Helicobacter pylori's proteins CagA and HspB induces cell proliferation in AGS gastric epithelial cells, independently from the bacterial infection. 63(19), 6350-6356.

J Kusters (2001) Recent Developments in Helicobacter pylori Vaccination. 36(234), 15-21.

Xavier Calvet, María‐josé Ramírez Lázaro, Philippe Lehours, Francis Mégraud (2013) Diagnosis and Epidemiology of Helicobacter pylori Infection. 18(s1), 5-11.

Y Niv (2008) H pylori recurrence after successful eradication. 14(10), 1477.

K Robinson, R Argent, J Atherton (2007) The inflammatory and immune response to Helicobacter pylori infection. 21(2), 237-259.

J Taylor, M Ziman, J Huff, N Moroski, M Vajdy (2000) The Journal of experimental medicine. 191, 1467-1476.

Marta Marchetti, Beatrice Aricò, Daniela Burroni, Natale Figura, Rino Rappuoli, Paolo Ghiara (1995) Development of a Mouse Model of Helicobacter pylori Infection that Mimics Human Disease. 267(5204), 1655-1658.

M Marchetti, M Rossi, V Giannelli, M Giuliani, M Pizza, S Censini (1998) Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. 16(1), 33-37.

C Lee (2001) Vaccination Against Helicobacter pylori in Non-Human Primate Models and Humans. 53(5), 437-442.

G Rossi, P Ruggiero, S Peppoloni, L Pancotto, D Fortuna, L Lauretti (2004) Therapeutic vaccination against Helicobacter pylori in the beagle dog experimental model: safety, immunogenicity, and efficacy. 72(6), 3252-3259.

M Stein, P Ruggiero, R Rappuoli, F Bagnoli (2013) Helicobacter pylori CagA: from pathogenic mechanisms to its use as an anti-cancer vaccine. 4.

P Ruggiero, S Censini (2014) Helicobacter pylori: A Brief History of a Still Lacking Vaccine. 2(2), 187-208.

Laurent Terradot, Gabriel Waksman (2011) Architecture of the Helicobacter pylori Cag‐type IV secretion system. 278(8), 1213-1222.

Wolfgang Fischer (2011) Assembly and molecular mode of action of the Helicobacter pylori Cag type IV secretion apparatus. 278(8), 1203-1212.

L Cendron, G Zanotti (2011) Structural and functional aspects of unique type IV secretory components in the Helicobacter pylori cag-pathogenicity island. 278(8), 1223-1231.

K Stingl, S Müller, G Scheidgen-Kleyboldt, M Clausen, B Maier (2010) Composite system mediates two-step DNA uptake into Helicobacter pylori. 107(3), 1184-1189.